1. Home
  2. EXEL vs BALL Comparison

EXEL vs BALL Comparison

Compare EXEL & BALL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exelixis Inc.

EXEL

Exelixis Inc.

N/A

Current Price

$65.20

Market Cap

17.8B

Sector

Health Care

ML Signal

N/A

Logo Ball Corporation

BALL

Ball Corporation

N/A

Current Price

$63.78

Market Cap

17.1B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
EXEL
BALL
Founded
1994
1880
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Containers/Packaging
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
17.8B
17.1B
IPO Year
2000
2009

Fundamental Metrics

Financial Performance
Metric
EXEL
BALL
Price
$65.20
$63.78
Analyst Decision
Buy
Buy
Analyst Count
17
14
Target Price
$61.36
★ $72.62
AVG Volume (30 Days)
★ 2.4M
2.0M
Earning Date
10-29-2026
11-03-2026
Dividend Yield
N/A
★ 1.26%
EPS Growth
★ 57.95
N/A
EPS
★ 2.46
1.25
Revenue
★ $452,477,000.00
N/A
Revenue This Year
$10.14
$17.83
Revenue Next Year
$12.56
$3.02
P/E Ratio
★ $26.76
$50.80
Revenue Growth
N/A
N/A
52 Week Low
$39.71
$46.65
52 Week High
$73.69
$69.58

Technical Indicators

Market Signals
Indicator
EXEL
BALL
Relative Strength Index (RSI) 45.48 48.74
Support Level $55.28 $60.66
Resistance Level $73.69 $66.34
Average True Range (ATR) 2.42 1.92
MACD -0.88 -0.46
Stochastic Oscillator 1.60 15.75

Price Performance

Historical Comparison
EXEL
BALL

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

About BALL Ball Corporation

Ball is the world's largest metal can manufacturer with market share over 30% in its three main regions (North America, Europe, and South America). The company is focused on increasing capacity amid a wave of new developed-market demand, while also investing in faster-growing emerging-market economies. Ball spun-off its glass jar business in 1993 and is now owned by Newell. The company reports three segments—beverage packaging, North and Central America (48% of 2025 revenue), beverage packaging, EMEA (30%), beverage packaging, South America (16%)—and it generated $13 billion in revenue in 2025.

Share on Social Networks: